Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
69
Active, not recruiting, industry sponsors, Infectious disease and vaccines, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,960
69 trials
Showing 1 to 25, recently updated first.
- A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and OlderPivotal-lookingActive, not recruiting
Shenzhen Shenxin Biotechnology Co., LtdIndustry
NCT07128121 · 500 participants (planned) · Start Aug 13, 2025 · Primary completion Oct 2029
Drug: Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006); Placebo · For: Respiratory Syncytial Virus (RSV) Infection
Sites: Changsha, China
- Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT02932150 · 150 participants (planned) · Start Nov 2016 · Primary completion Oct 27, 2026
Drug: TAF; Placebo · For: Chronic Hepatitis B
Sites: Los Angeles, California; San Diego, California; San Francisco, California · 39 sites in all
- A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.Pivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT07228390 · 128 participants · Start Nov 13, 2025 · Primary completion Dec 8, 2026
Drug: Ritlecitinib; Placebo · For: Hidradenitis Suppurativa
Sites: Hot Springs, Arkansas; Fountain Valley, California; Northridge, California · 57 sites in all
- A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)Pivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06537414 · 283 participants · Start Nov 11, 2024 · Primary completion May 31, 2027
Drug: Daplusiran/Tomligisiran Dose Level 1; Daplusiran/Tomligisiran Dose Level 2 and 2 more · For: Chronic Hepatitis B Virus Infection; Hepatitis B
Sites: San Francisco, California; San Jose, California; Minneapolis, Minnesota · 80 sites in all
- Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)Pivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06497504 · 153 participants · Start Sep 17, 2024 · Primary completion Apr 22, 2027
Drug: Bepirovirsen; Placebo · For: Hepatitis B
Sites: Bakersfield, California; San Francisco, California; Orlando, Florida · 51 sites in all
- A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06524414 · 605 participants · Start Jul 25, 2024 · Primary completion Mar 4, 2027
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) and 1 more · For: Pneumococcal Disease
Sites: Fayetteville, Arkansas; Jonesboro, Arkansas; La Puente, California · 67 sites in all
- Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)Active, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04954859 · 366 participants · Start Dec 14, 2021 · Primary completion Jan 24, 2029
Drug: Bepirovirsen; Placebo · For: Hepatitis B
Sites: Sacramento, California; San Jose, California; Colorado Springs, Colorado · 161 sites in all
- A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)Pivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT05996471 · 185 participants · Start Aug 17, 2023 · Primary completion May 27, 2026
Drug: VH3810109; Cabotegravir and 2 more · For: HIV Infections
Sites: Birmingham, Alabama; Bakersfield, California; Los Angeles, California · 45 sites in all
- A Study of Zasocitinib in Adults With Hidradenitis SuppurativaActive, not recruiting
TakedaTakeda (TAK)
NCT07244263 · 91 participants · Start Jan 26, 2026 · Primary completion Feb 5, 2027
Drug: Zasocitinib (Dose A) · For: Hidradenitis Suppurativa
Sites: Scottsdale, Arizona; Fort Smith, Arkansas; Fountain Valley, California · 45 sites in all
- A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07717840 · 164 participants · Start Jul 8, 2026 · Primary completion Oct 1, 2026
Drug: AZD6489; Licensed RSV vaccine #1 and 1 more · For: RSV Respiratory Syncytial Virus
Sites: Long Beach, California; Rolling Hills Estates, California; Chicago, Illinois · 6 sites in all
- A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus InfectionActive, not recruiting
Suzhou HepaThera Biotech Co., Ltd.Industry
NCT07183306 · 86 participants · Start Dec 30, 2024 · Primary completion Aug 24, 2027
Drug: HT-101; HT-102 · For: Chronic Hepatitis B
Sites: Beijing, China; Xiamen, China; Guangzhou, China · 7 sites in all
- A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus InfectionActive, not recruiting
Suzhou HepaThera Biotech Co., Ltd.Industry
NCT07245953 · 60 participants (planned) · Start Nov 5, 2025 · Primary completion Feb 2027
Drug: HT-101; HT-102 and 2 more · For: Chronic Hepatitis B
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 12 sites in all
- A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06749457 · 242 participants · Start Dec 30, 2024 · Primary completion Mar 8, 2027
Drug: AZD7760 · For: Staphylococcus Aureus
Sites: Huntsville, Alabama; Chula Vista, California; Glendale, California · 40 sites in all
- Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older AdultsPivotal-lookingActive, not recruiting
Clover Biopharmaceuticals AUS PtyIndustry
NCT06984094 · 612 participants · Start Jun 18, 2025 · Primary completion Mar 2028
Drug: SCB-1019T; SCB-1022 and 2 more · For: RSV Infection; Human Metapneumovirus Infection; Parainfluenza Infection
Sites: Adelaide, Australia; Melbourne, Australia; Perth, Australia
- A Study With CIT-013 in HS PatientsPivotal-lookingActive, not recruiting
Citryll BVIndustry
NCT06993233 · 108 participants · Start Oct 31, 2025 · Primary completion Apr 2027
Drug: CIT-013 high dose; CIT-013 medium dose and 1 more · For: Hidradenitis Suppurativa (HS)
Sites: Barrie, Canada; Calgary, Canada; London, Canada · 28 sites in all
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefensePivotal-lookingActive, not recruiting
Zura Bio IncIndustry
NCT06993610 · 247 participants · Start May 16, 2025 · Primary completion Sep 18, 2026
Drug: Tibulizumab Dose A; Tibulizumab Dose B · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 61 sites in all
- A Study Evaluating BFB759 in Moderate to Severe Hidradenitis SuppurativaPivotal-lookingActive, not recruiting
Bluefin Biomedicine, Inc.Industry
NCT07287644 · 210 participants (planned) · Start Nov 3, 2025 · Primary completion Aug 1, 2027
Drug: BFB759 · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Encino, California; Huntington Beach, California · 64 sites in all
- A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07128615 · 405 participants · Start Sep 4, 2025 · Primary completion Jan 28, 2026
Drug: AZD4117; AZD5315 · For: Influenza A
Sites: Long Beach, California; Rolling Hills Estates, California; Miami Lakes, Florida · 14 sites in all
- A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 InfectionPivotal-lookingActive, not recruiting
VaxartIndustry
NCT06672055 · 5,485 participants (planned) · Start Oct 8, 2024 · Primary completion May 2027
Drug: VXA-CoV2-3.1; COMIRNATY® and 1 more · For: SARS-CoV2; COVID-19
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 145 sites in all
- A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Active, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06035497 · 83 participants (planned) · Start Nov 20, 2023 · Primary completion Aug 11, 2026
Drug: BMS-986369 · For: Relapsed or Refractory T-cell Lymphomas
Sites: Anjo-shi, Japan; Nagoya, Japan; Toyohashi, Japan · 40 sites in all
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)Pivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT06741397 · 229 participants · Start Dec 20, 2024 · Primary completion Sep 9, 2026
Drug: CAB LA; New formulation of CAB LA · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Palm Springs, California · 27 sites in all
- LMN-201 for Prevention of C. Difficile Infection RecurrencePivotal-lookingActive, not recruiting
Lumen Bioscience, Inc.Industry
NCT05330182 · 375 participants (planned) · Start Aug 29, 2024 · Primary completion Aug 31, 2026
Drug: LMN-201; Placebo · For: Clostridioides Difficile Infection
Sites: Escondido, California; Hamden, Connecticut; Tampa, Florida · 15 sites in all
- Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06956235 · 149 participants · Start Jun 9, 2025 · Primary completion Apr 2, 2026
Drug: Tulisokibart; Placebo · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Phoenix, Arizona; Rogers, Arkansas · 68 sites in all
- Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.Active, not recruiting
Vasomune Therapeutics, Inc.Industry
NCT05123755 · 60 participants · Start Dec 20, 2021 · Primary completion Sep 2026
Drug: AV-001 Injection; AV-001 Placebo Injection · For: Acute Respiratory Distress Syndrome; Viral or Bacterial Infections; Pneumonia and 3 more
Sites: Newport Beach, California; Denver, Colorado; Chicago, Illinois · 6 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07092865 · 168 participants · Start Aug 6, 2025 · Primary completion Jan 12, 2027
Drug: Adjuvanted RSVPreF3 vaccine · For: Respiratory Syncytial Virus Infections
Sites: Lexington, Kentucky; St Louis, Missouri; Omaha, Nebraska · 38 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.